Christopher M. Starr - Mar 31, 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Director
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
4/1/2022, 05:02 PM
Previous filing
Feb 4, 2022
Next filing
Jul 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +2.86K +66.58% 7.15K Mar 31, 2022 Direct F1
holding MNPR Common Stock 49.4K Mar 31, 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -2.86K -25% $0.00 8.58K Mar 31, 2022 Common Stock 2.86K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 49,400 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.
F3 On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.